Skip to main content
Premium Trial:

Request an Annual Quote

Valentis Licenses GeneSwitch to Schering, Pockets $1.1M

NEW YORK, Dec. 20 - Schering will pay Valentis $1.1 million for the right to use its GeneSwitch gene-regulation technology for internal drug discovery.

 

Terms of the deal also call for Schering to get exclusive, worldwide rights to Valentis' PINC polymer-based synthetic gene-delivery technology. The German pharma firm said it will use GeneSwitch in up to two of its genes and consider an option for non-exclusive rights to the PINC technology for a third gene.

 

Click here for more information.